South Korea · Delayed Price · Currency is KRW ST Pharm Statistics
Total Valuation
ST Pharm has a market cap or net worth of KRW 2.94 trillion. The enterprise value is 2.93 trillion.
| Market Cap | 2.94T |
| Enterprise Value | 2.93T |
Important Dates
The next estimated earnings date is Tuesday, April 28, 2026.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
ST Pharm has 20.83 million shares outstanding. The number of shares has increased by 9.95% in one year.
| Current Share Class | 20.83M |
| Shares Outstanding | 20.83M |
| Shares Change (YoY) | +9.95% |
| Shares Change (QoQ) | +14.58% |
| Owned by Insiders (%) | 7.33% |
| Owned by Institutions (%) | 13.83% |
| Float | 13.11M |
Valuation Ratios
The trailing PE ratio is 52.49 and the forward PE ratio is 46.26. ST Pharm's PEG ratio is 1.68.
| PE Ratio | 52.49 |
| Forward PE | 46.26 |
| PS Ratio | 8.86 |
| PB Ratio | 4.96 |
| P/TBV Ratio | 5.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 210.08 |
| PEG Ratio | 1.68 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 34.50, with an EV/FCF ratio of -88.45.
| EV / Earnings | 53.21 |
| EV / Sales | 8.82 |
| EV / EBITDA | 34.50 |
| EV / EBIT | 53.27 |
| EV / FCF | -88.45 |
Financial Position
The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.26 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.93 |
| Debt / FCF | -2.38 |
| Interest Coverage | 13.61 |
Financial Efficiency
Return on equity (ROE) is 9.96% and return on invested capital (ROIC) is 9.30%.
| Return on Equity (ROE) | 9.96% |
| Return on Assets (ROA) | 4.56% |
| Return on Invested Capital (ROIC) | 9.30% |
| Return on Capital Employed (ROCE) | 8.89% |
| Weighted Average Cost of Capital (WACC) | 6.11% |
| Revenue Per Employee | 506.38M |
| Profits Per Employee | 83.96M |
| Employee Count | 655 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 1.34 |
Taxes
In the past 12 months, ST Pharm has paid 4.16 billion in taxes.
| Income Tax | 4.16B |
| Effective Tax Rate | 7.09% |
Stock Price Statistics
The stock price has increased by +110.12% in the last 52 weeks. The beta is 0.35, so ST Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +110.12% |
| 50-Day Moving Average | 150,562.00 |
| 200-Day Moving Average | 113,114.00 |
| Relative Strength Index (RSI) | 47.07 |
| Average Volume (20 Days) | 126,533 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ST Pharm had revenue of KRW 331.68 billion and earned 54.99 billion in profits. Earnings per share was 2,688.35.
| Revenue | 331.68B |
| Gross Profit | 132.42B |
| Operating Income | 54.93B |
| Pretax Income | 58.72B |
| Net Income | 54.99B |
| EBITDA | 84.81B |
| EBIT | 54.93B |
| Earnings Per Share (EPS) | 2,688.35 |
Balance Sheet
The company has 90.99 billion in cash and 78.71 billion in debt, with a net cash position of 12.28 billion or 589.39 per share.
| Cash & Cash Equivalents | 90.99B |
| Total Debt | 78.71B |
| Net Cash | 12.28B |
| Net Cash Per Share | 589.39 |
| Equity (Book Value) | 593.00B |
| Book Value Per Share | 28,666.39 |
| Working Capital | 207.92B |
Cash Flow
In the last 12 months, operating cash flow was 13.99 billion and capital expenditures -47.07 billion, giving a free cash flow of -33.08 billion.
| Operating Cash Flow | 13.99B |
| Capital Expenditures | -47.07B |
| Depreciation & Amortization | 29.88B |
| Net Borrowing | -9.42B |
| Free Cash Flow | -33.08B |
| FCF Per Share | -1,588.34 |
Margins
Gross margin is 39.92%, with operating and profit margins of 16.56% and 16.58%.
| Gross Margin | 39.92% |
| Operating Margin | 16.56% |
| Pretax Margin | 17.70% |
| Profit Margin | 16.58% |
| EBITDA Margin | 25.57% |
| EBIT Margin | 16.56% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.35%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 0.35% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.32% |
| Buyback Yield | -9.95% |
| Shareholder Yield | -9.59% |
| Earnings Yield | 1.87% |
| FCF Yield | -1.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ST Pharm has an Altman Z-Score of 7.09 and a Piotroski F-Score of 5.
| Altman Z-Score | 7.09 |
| Piotroski F-Score | 5 |